Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

Eligible patients for this study must have a diagnosis of a neurological disorder affecting
the brain of at least 3 months duration prior to baseline and which is not rapidly
progressing and must have a diagnosis of Pseudobulbar affect (PBA).

This is a multicenter, open label study consisting of 6 months of treatment.

Approximately 125 patients will be enrolled at approximately 25 centers in the United
States.

Inclusion Criteria:

- Diagnosis of a neurological disorder affecting the brain (e.g. Alzheimer's and other
dementias, stroke, Trauma Brain Injury, Multiple Sclerosis, Amyotrophic Lateral
Sclerosis, Huntington's disease, Parkinson's disease) of at least 3 months duration
prior to baseline and which is not rapidly progressing

- Diagnosis of Pseudobulbar Affect (PBA)

- A Center for Neurologic Study-Lability Scale (CNS-LS) score of 13 or greater at
Baseline

- Minimum Data Set (MDS) information for patient available within 60 days prior to
Baseline

- Informant who is willing to comply with study procedures

Exclusion Criteria:

- Patients who have received NUEDEXTA® in the past 1 year

- Patients with the diagnosis of Severe Depressive Disorder that would interfere with
the conduct of the study

- Patients who have a history of schizophrenia spectrum and other psychotic disorders

- Patients with co-existent clinically significant or unstable systemic diseased that
could confound the interpretation of the safety results of the study
(e.g.,malignancy, poorly controlled diabetes, poorly controlled hypertension,
unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease,
dilated cardiomyopathy, or unstable valvular heart disease)

- Patients with myasthenia gravis